MorphoSys AG
XETRA:MOR

Watchlist Manager
MorphoSys AG Logo
MorphoSys AG
XETRA:MOR
Watchlist
Price: 67.25 EUR 0.37%
Market Cap: 2.5B EUR

Relative Value

There is not enough data to reliably calculate the relative value of MOR.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MOR Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
12.5
Median 5Y
9.7
Industry
8
Forward
10.8
vs History
vs Industry
Median 3Y
-5.5
Median 5Y
-5.5
Industry
23.5
Forward
-15.3
vs History
vs Industry
Median 3Y
-8.5
Median 5Y
-4.3
Industry
21.9
vs History
vs Industry
Median 3Y
-8.2
Median 5Y
-2.4
Industry
24.3
vs History
vs Industry
Median 3Y
-9.7
Median 5Y
-6.2
Industry
3.2
vs History
vs Industry
Median 3Y
10.6
Median 5Y
6.2
Industry
8.1
Forward
9.2
vs History
vs Industry
Median 3Y
12.6
Median 5Y
7.5
Industry
10.1
vs History
vs Industry
Median 3Y
-5
Median 5Y
-3.7
Industry
5.9
Forward
-13.6
vs History
vs Industry
Median 3Y
-4.9
Median 5Y
-3.6
Industry
6.2
Forward
-11.3
vs History
vs Industry
Median 3Y
-7.2
Median 5Y
-2.9
Industry
7.7
vs History
vs Industry
Median 3Y
-7.2
Median 5Y
-3.7
Industry
6.3
vs History
vs Industry
Median 3Y
1.9
Median 5Y
1.9
Industry
5.6

Multiples Across Competitors

MOR Competitors Multiples
MorphoSys AG Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DE
MorphoSys AG
XETRA:MOR
2.5B EUR 12.4 -5.5 -5 -4.9
IL
Can Fite Biopharma Ltd
TASE:CANF
172T ILS 62 044 059.1 -4 260 786.8 -4 181 136.2 -4 171 829.1
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 968 621.2 -161 447.8 -196 049.2 -193 812
US
Abbvie Inc
NYSE:ABBV
412.5B USD 6.9 175.7 16.9 24
US
Amgen Inc
NASDAQ:AMGN
183.8B USD 5.1 26.2 18.8 18.8
US
Gilead Sciences Inc
NASDAQ:GILD
154.4B USD 5.3 19 12.8 12.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
123B USD 10.5 33.5 24.6 25.7
US
Epizyme Inc
F:EPE
94.1B EUR 2 073.9 -529.2 -576.3 -560.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
85.5B USD 6 18.7 17.9 20.3
AU
CSL Ltd
ASX:CSL
84.5B AUD 3.6 18.9 12.7 15.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
55.7B USD 17.3 1 278.1 172.4 209.1
P/S Multiple
Revenue Growth P/S to Growth
DE
MorphoSys AG
XETRA:MOR
Average P/S: 8 728 620.1
12.4
24%
0.5
IL
C
Can Fite Biopharma Ltd
TASE:CANF
62 044 059.1
140%
443 171.9
FR
Pharnext SCA
OTC:PNEXF
33 968 621.2
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.9
9%
0.8
US
Amgen Inc
NASDAQ:AMGN
5.1
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.3
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.5
10%
1
US
E
Epizyme Inc
F:EPE
2 073.9
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
6
6%
1
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
17.3
46%
0.4
P/E Multiple
Earnings Growth PEG
DE
MorphoSys AG
XETRA:MOR
Average P/E: 224.3
Negative Multiple: -5.5
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -4 260 786.8 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 447.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
175.7
89%
2
US
Amgen Inc
NASDAQ:AMGN
26.2
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
33.5
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -529.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.7
10%
1.9
AU
CSL Ltd
ASX:CSL
18.9
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 278.1
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DE
MorphoSys AG
XETRA:MOR
Average EV/EBITDA: 39.5
Negative Multiple: -5
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -4 181 136.2 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 049.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.9
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.8
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.6
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -576.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
11%
1.6
AU
CSL Ltd
ASX:CSL
12.7
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
172.4
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DE
MorphoSys AG
XETRA:MOR
Average EV/EBIT: 46.7
Negative Multiple: -4.9
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -4 171 829.1 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 812 N/A N/A
US
Abbvie Inc
NYSE:ABBV
24
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.8
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.7
16%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -560.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
20.3
13%
1.6
AU
CSL Ltd
ASX:CSL
15.9
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
209.1
N/A N/A